Navigation Links
Savient Pharmaceuticals Receives Complete Response Letter from U.S. Food and Drug Administration for KRYSTEXXA(TM)
Date:8/2/2009

all and will be available for 14 days. To access the recording, use the dial-in number and the Conference ID listed below.

Dial: 888-203-1112 (domestic) or 719-457-0820 (international)

Conf ID: 9640146

ABOUT SAVIENT PHARMACEUTICALS, INC.

Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and marketing pharmaceutical products that target unmet medical needs in both niche and broader specialty markets. Savient has developed one product: KRYSTEXXA(TM) (pegloticase) which is a PEGylated uricase enzyme intended for the treatment of chronic gout in patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA, formerly referred to as Puricase(R), from Duke University and Mountain View Pharmaceuticals, Inc. Savient also manufactures and supplies Oxandrin(R) (oxandrolone tablets, USP) CIII in the U.S. Further information on Savient can be accessed by visiting: http://www.savient.com. Puricase is a registered trademark of Mountain View Pharmaceuticals, Inc.

FORWARD-LOOKING LANGUAGE

All statements other than statements of historical facts included in this press release are forward-looking statements that are subject to certain risks, trends and uncertainties that could cause actual results and achievements to differ materially from those expressed in such statements. These risks, trends and uncertainties are in some instances beyond our control. Words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "will" and other similar expressions identify forward-looking statements, although not all forward-looking statements contain these identifying words. In particular, any statements regarding potential FDA marketing approval for KRYSTEXXA(TM
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

3

GOOD

Page: 1 2 3 4 5 6

Related medicine news :

1. Savient Pharmaceuticals to Present at the Credit Suisse Phoenix Healthcare Conference on November 13th
2. Savients Board of Directors Forms a Board Committee to Oversee the Regulatory and Pre-Launch Activities for Pegloticase
3. Savient Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference on January 14th
4. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results
5. Savient Pharmaceuticals to Present at The Cowen and Company 29th Annual Healthcare Conference on March 17, 2009
6. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
7. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
10. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
11. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...,Minn.,Nov.25/PRNewswire-USNewswire/--Whenmostpeop...iropractorcanalsogivepatientsthehelptheyneed.TMJst...rjaw(mandible)contacts/connectswithyourskull(tempo...hTMJdysfunctionarepainwithchewing,clickingorpoppin...sfunctionincluding:headaches,fatigue,sleepdisturba...
(Date:11/25/2009)...TO,Nov.25/PRNewswire/-SentinelleMedicalInc.,aleadi...tionsoftwarelaunchesasuiteofnewleadingedgeclinical...atformatthisyear,sRadiologicalSocietyofNorthAmeric...oth5800,HallA).Theapplicationsleveragetheuniquehig...Iimagingcoilsandsupportmultipleimagingmodalitiesfo...
(Date:11/25/2009)...ANCISCO,Nov.25/PRNewswire/--TheBayAreaAirQualityMa... Spare the Air Alert forThursday,Novem...soranyothersolidfuel,bothindoorsandoutdoors. ,,...litytomorrow,"saidJackBroadbent,executiveofficerof...ctthehealthoftheirneighborsandfellowcommunitymembe...
(Date:11/25/2009)...ous discovery that grew out of a collaboration bet...ly offer hope to the nearly 10 million Americans w... Also known as hardening of the arteries, periphe...ory problem in which narrowed arteries reduce bloo... red flag for vascular disease, heart attack and s...
(Date:11/25/2009)... Evaluation and treatment clinics to r...oodstock (Vocus) November 25, 2009 -- Centegra Hea...nes and H1N1 vaccine shots at four Centegra Primar...pment of vaccine has arrived. The clinics are at C...cHenry and will be open as follows: ,   ...
Breaking Medicine News(10 mins):Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 2Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 3Health News:Winter Spare the Air Alert in Effect for Thursday, November 26, 2009 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 3Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 4Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 2Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 3Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 4
... Exposure to estrogens in the early stages of the ...s is a factor cited by the scientists for the deve...f life. // The study, done in an animal mode... of estrogens (xenoestrogens) are widespread in th...
... Students of Delhi University will soon be evaluat...cademic reform measures being introduced. // ...ancellor earlier this year, the academic reform co... top priorities for the committee and we want to m...
... Medical services in state-run hospitals across th...to work after 20 days of anti-quota protests follo...OPD services in premier health institutions like A...government hospitals in West Bengal, Karnataka, Ut...
... With the medicos' agitation against reservation c... withdraw it // , the casualty ward of the MKCG Me... a group of people who alleged that negligence cau... 'We brought him to the hospital immediately af...
... India and Singapore have agreed to cooperate in s...ism, //money laundering, organized crime and drugs...agement. "The two sides decided to cooperate ...ment," a senior official told PTI Wednesday here. ...
... New Delhi. Taking serious note of the plight of ... protesting medicos to call off their strike //for...tive action against them. Observing that the...orm of dissent. "Whatever Government does is ...
Other Medicine News:Health News:Prostate Cancer Risk Linked To Early Estrogen Exposure 2Health News:Students to Evaluate the Performance of Teachers 2
(Date:11/25/2009)...Newswire-FirstCall/--Pharmasset,Inc.(Nasdaq: VRUS ...scovering,developingandcommercializingnoveldrugsto...efiscalyearendedSeptember30,2009.AtSeptember30,200...ndshortterminvestments. ,, PipelineUpdateand20... ,, InlateNovember2009,anindependentDataMonito...
(Date:11/25/2009)...ire/--BioTrendsResearchGroup,Inc.releasedWave1ofit...amulti-phasesyndicatedmarketresearchprojecttrackin...ductlaunchthroughthefirstsixmonthsofavailability.E...rom75uniqueDermatologistsandqualitativeinformation...ra,obstaclestouse,typicalpatienttypes,productperce...
(Date:11/25/2009)...RNewswire-USNewswire/--RemediumTechnologiesInc.,ac...erebleeding,wonfirstprizeand$10,000intheMostPromis...e2009,companyofficialsannouncetoday. ,, Selecte...,steampitchedtheirinventionattheGSCSecuritySummitc...medium( www.remediumtechnologies.com )isdeveloping...
Breaking Medicine Technology:Pharmasset Reports Fiscal Year End 2009 Financial Results 2Pharmasset Reports Fiscal Year End 2009 Financial Results 3Pharmasset Reports Fiscal Year End 2009 Financial Results 4Pharmasset Reports Fiscal Year End 2009 Financial Results 5Pharmasset Reports Fiscal Year End 2009 Financial Results 6Pharmasset Reports Fiscal Year End 2009 Financial Results 7Pharmasset Reports Fiscal Year End 2009 Financial Results 8Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotech's New Psoriasis Agent Stelara (ustekinumab) is High 2Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 2Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 3Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A S on LNA Drug Platform 13659 1Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A S on LNA Drug Platform 13659 2Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A S on LNA Drug Platform 13659 3Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A S on LNA Drug Platform 13659 4Bavarian Nordic in Negotiations With the US Authorities for the Further Development of IMVAMUNE 28R 29 13656 1Bavarian Nordic in Negotiations With the US Authorities for the Further Development of IMVAMUNE 28R 29 13656 2Santaris Pharma A S Forms Strategic Alliance With Shire plc to Develop RNA Based Medicines for the Treatment of Rare Genetic Disorders 13655 1Santaris Pharma A S Forms Strategic Alliance With Shire plc to Develop RNA Based Medicines for the Treatment of Rare Genetic Disorders 13655 2Santaris Pharma A S Forms Strategic Alliance With Shire plc to Develop RNA Based Medicines for the Treatment of Rare Genetic Disorders 13655 3Santaris Pharma A S Forms Strategic Alliance With Shire plc to Develop RNA Based Medicines for the Treatment of Rare Genetic Disorders 13655 4
...SAN MATEO, Calif., Jan. 8 Corthera Inc. today ann...hase II clinical trial of,Relaxin, a naturally occ...,acute heart failure and other acute care illnesse...afety of Relaxin in,patients with acute heart fail...from more than 50 investigational centers worldwid...
...DEERFIELD, Ill., Jan. 7 Baxter International,Inc....ed pre-clinical,programs to develop recombinant Fa...l develop both an unmodified recombinant Factor IX...and a chemically modified, long-acting,version of ...leeding in,hemophilia B patients. Hemophilia B is ...
Other Medicine Technology:Corthera Initiates Phase II Clinical Trial of Relaxin in Acute Heart Failure 2Baxter Announces Recombinant Factor IX Development Program For Hemophilia B 2Baxter Announces Recombinant Factor IX Development Program For Hemophilia B 3
...ional reference laboratory and a worldwide leader ... ARUP offers an extensive test menu of highly comp...mic pathology. Owned by the University of Utah, AR... the nation's university teaching hospitals and ch...
...ional reference laboratory and a worldwide leader ... ARUP offers an extensive test menu of highly comp...mic pathology. Owned by the University of Utah, AR... the nation's university teaching hospitals and ch...
...ional reference laboratory and a worldwide leader ... ARUP offers an extensive test menu of highly comp...mic pathology. Owned by the University of Utah, AR... the nation's university teaching hospitals and ch...
...ional reference laboratory and a worldwide leader ... ARUP offers an extensive test menu of highly comp...mic pathology. Owned by the University of Utah, AR... the nation's university teaching hospitals and ch...
Medicine Products: